Nelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings

References

• SocietyACCervical Cancer Key StatisticsCancer ResearchUK2015
   Google Scholar
• World Health OrganizationWorld Cancer Report 2014GenevaWorld Health Organization2014
   Google Scholar
• WalboomersJMJacobsMVManosMMHuman papillomavirus is a necessary cause of invasive cervical cancer worldwideJ Pathol19991891121910451482
   PubMed Web of Science ®Google Scholar
• HolowatyPMillerABRohanTToTNatural history of dysplasia of the uterine cervixJ Natl Cancer Inst199991325225810037103
   PubMedGoogle Scholar
• EifelPJWinterKMorrisMPelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01J Clin Oncol200422587288014990643
   PubMed Web of Science ®Google Scholar
• AhdiehLKleinRSBurkRPrevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative womenJ Infect Dis2001184668269011517428
   PubMed Web of Science ®Google Scholar
• WrightTCJrEllerbrockTVChiassonMAVan DevanterNSunXWCervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease StudyObstet Gynecol19948445915978090399
   PubMed Web of Science ®Google Scholar
• ContiMAgarossiAParazziniFHPV, HIV infection, and risk of cervical intraepithelial neoplasia in former intravenous drug abusersGynecol Oncol19934933443488390961
   PubMed Web of Science ®Google Scholar
• NastiGMartellottaFBerrettaMImpact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcomaCancer200398112440244614635079
   PubMed Web of Science ®Google Scholar
• MinkoffHAhdiehLMassadLSThe effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected womenAIDS200115162157216411684935
   PubMed Web of Science ®Google Scholar
• BernsteinWBDennisPARepositioning HIV protease inhibitors as cancer therapeuticsCurr Opin HIV AIDS20083666667519373040
   PubMed Web of Science ®Google Scholar
• XieLEvangelidisTXieLBournePEDrug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavirPLoS Comput Biol201174e100203721552547
   PubMed Web of Science ®Google Scholar
• BruningABurgerPVogelMNelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosisCancer Biol Ther20098322623219106637
   PubMed Web of Science ®Google Scholar
• GillsJJLopiccoloJDennisPANelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagyAutophagy20084110710918000394
   PubMed Web of Science ®Google Scholar
• BruningARahmehMFrieseKNelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulationMol Oncol2013761012101823916134
   PubMed Web of Science ®Google Scholar
• GillsJJLopiccoloJTsurutaniJNelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivoClin Cancer Res200713175183519417785575
   PubMed Web of Science ®Google Scholar
• WangZHLiLPengZLDuanZLEffect of autophagy gene Beclin 1 on the growth of cervical cancer HeLa cells in vitro and vivoZhonghua Zhong Liu Za Zhi2011331180480922335943
   PubMedGoogle Scholar
• MizushimaNYoshimoriTLevineBMethods in mammalian autophagy researchCell2010140331332620144757
   PubMed Web of Science ®Google Scholar
• QuXYuJBhagatGPromotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy geneJ Clin Invest2003112121809182014638851
   PubMed Web of Science ®Google Scholar
• ZhuWPanXLiFZhangYLuXExpression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survivalTumour Biol20123351653165922648564
   PubMedGoogle Scholar
• SunYZhangJPengZLBeclin1 induces autophagy and its potential contributions to sensitizes SiHa cells to carboplatin therapyInt J Gynecol Cancer200919477277619509586
   PubMed Web of Science ®Google Scholar
• DonatoNJPerezMKangHSiddikZHLingYHPerez-SolerREGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivityClin Cancer Res20006119320210656450
   PubMed Web of Science ®Google Scholar
• DelaneyJRPatelCMcCabeKEA strategy to combine pathway-targeted low toxicity drugs in ovarian cancerOncotarget2015631311043111826418751
   PubMedGoogle Scholar
• UrienSLokiecFPopulation pharmacokinetics of total and unbound plasma cisplatin in adult patientsBr J Clin Pharmacol200457675676315151521
   PubMed Web of Science ®Google Scholar
• SuHWangXp62 Stages an interplay between the ubiquitin-proteasome system and autophagy in the heart of defense against proteotoxic stressTrends Cardiovasc Med201121822422822902070
   PubMed Web of Science ®Google Scholar
• YuHSuJXuYp62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteinsEur J Cancer201147101585159421371883
   PubMed Web of Science ®Google Scholar
• McCabeKEBacosKLuDTriggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinomaCell Death Dis20145e149625356865
   PubMed Web of Science ®Google Scholar
• XiangTDuLPhamPZhuBJiangSNelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathwayCancer Lett20153641798825937300
   PubMed Web of Science ®Google Scholar
• BruningAVogelMMylonasIFrieseKBurgesABortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavirCurr Cancer Drug Targets201111779980921762082
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NWeinsteinJNCollissonEAMillsGBThe Cancer Genome Atlas Pan-Cancer analysis projectNat Genet201345101113112024071849
   PubMed Web of Science ®Google Scholar
• GaoJAksoyBADogrusozUIntegrative analysis of complex cancer genomics and clinical profiles using the cBioPortalSci Signal201362691
   Web of Science ®Google Scholar
• EspositoVPalescandoloESpugniniEPEvaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinomaClin Cancer Res20061282634263916638877
   PubMed Web of Science ®Google Scholar
• LebbeCBlumLPelletCClinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcomaAIDS1998127F45F499619797
   PubMed Web of Science ®Google Scholar
• BlumensteinJJCopelandTDOroszlanSMichejdaCJSynthetic non-peptide inhibitors of HIV proteaseBiochem Biophys Res Commun198916329809872675834
   PubMed Web of Science ®Google Scholar
• BeschCLAntiretroviral therapy in drug-naive patients infected with human immunodeficiency virusAm J Med Sci200432813915254436
   PubMed Web of Science ®Google Scholar
• JarvisBFauldsDNelfinavir. A review of its therapeutic efficacy in HIV infectionDrugs19985611471679664204
   PubMed Web of Science ®Google Scholar
• JohnsonCEHuntDKWiltshireMEndoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquineMol Oncol20159367568825498902
   PubMed Web of Science ®Google Scholar
• MathurAAbd ElmageedZYLiuXSubverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cellsPLoS One201498e10310925121735
   PubMed Web of Science ®Google Scholar
• HampsonLKitchenerHCHampsonINSpecific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitroAntivir Ther200611681382517310826
   PubMed Web of Science ®Google Scholar
• Utkina-SosunovaIVNiatsetskayaZVSosunovSARatnerVIMatsiukevichDTenVSNelfinavir inhibits intra-mitochondrial calcium influx and protects brain against hypoxic-ischemic injury in neonatal micePLoS One201384e6244823614049
   PubMed Web of Science ®Google Scholar
• PetersWA3rdLiuPYBarrettRJ2ndConcurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervixJ Clin Oncol20001881606161310764420
   PubMed Web of Science ®Google Scholar
• Duenas-GonzalezAZarbaJJPatelFPhase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervixJ Clin Oncol201129131678168521444871
   PubMed Web of Science ®Google Scholar
• RosePGDegeestKMcMeekinSFuscoNA phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group studyGynecol Oncol2007107227427917688925
   PubMed Web of Science ®Google Scholar
• DisaiaPJCreasmanWTClinical Gynecologic Oncology8th edPhiladelphia, PAElsevier2007
   Google Scholar
• RenganRMickRPrymaDA phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical responseJ Thorac Oncol20127470971522425919
   PubMed Web of Science ®Google Scholar
• BrunnerTBGeigerMGrabenbauerGGPhase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancerJ Clin Oncol200826162699270618509182
   PubMed Web of Science ®Google Scholar
• BlumenthalGMGillsJJBallasMSA phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumorsOncotarget20145188161817225327558
   PubMedGoogle Scholar